SLC5A2 and type 2 diabetes mellitus: In addition, early treatment with an SGLT-2 inhibitor in subjects with a recent acute myocardial infarction, pre-existing T2DM and established HF was shown to produce a significant decrease in plasma volume status after long-term treatment, equal to 24 weeks [26].